Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand

Authors: Lucia Guerra-Menéndez, Maria C Sádaba, Juan E Puche, Jose L Lavandera, Luis F de Castro, Arancha R de Gortázar, Inma Castilla-Cortázar

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Bone is one of the major target tissues for Insulin-like Growth Factor I (IGF-I). Low doses of IGF-I were able to improve liver-associated osteopenia. In the present work, a model of partial IGF-I deficiency was used in order to provide insight into the mechanisms of the beneficial actions of IGF-I replacement therapy in bone.

Methods

Several proteins involved in osteoblastic/osteocyte and osteoclastic differentiation and activity were studied in the three experimental groups: control (CO) group (wild type mice, Igf+/+, n = 10), heterozygous Igf+/- group with partial IGF-I deficiency (Hz, n = 10), and heterozygous Igf+/- mice treated with IGF-I for 10 days (Hz + IGF-I, n = 10).

Results

Data in this paper confirm that the simple partial IGF-I deficiency is responsible for osteopenia, determined by densitometry and histopathology. These findings are associated with a reduced gene expression of osteoprotegerin, sclerostin, calcitonin receptor (CTR), insulin-like growth factor binding protein 5 and RUNX2. IGF-I replacement therapy normalized CTR gene expression and reduced markers of osteoclastic activity.

Conclusions

Low doses of IGF-I constituted a real replacement therapy that normalized IGF-I serum levels improving the expression of most of these proteins closely involved in bone-forming, and reducing bone resorption by mechanisms related to osteoprotegerin, RANKL and PTH receptor.
Appendix
Available only for authorised users
Literature
1.
Mohan S, Baylink DJ: Bone growth factors. Clin Orthop Relat Res. 1991, 263: 30-48.PubMed
2.
McCarthy TL, Centrella M, Canalis E: Insulin-like growth factor (IGF) and bone. Connect Tissue Res. 1989, 20 (1–4): 277-282.CrossRefPubMed
3.
Grinspoon SK, Baum HB, Peterson S, Klibanski A: Effects of rhIGF-I administration on bone turnover during short-term fasting. J Clin Invest. 1995, 96 (2): 900-906. 10.1172/JCI118137.PubMedCentralCrossRefPubMed
4.
5.
LeRoith D, Roberts CT: Insulin-like growth factors. Ann N Y Acad Sci. 1993, 692: 1-9. 10.1111/j.1749-6632.1993.tb26200.x.CrossRefPubMed
6.
Sara VR, Hall K: Insulin-like growth factors and their binding proteins. Physiol Rev. 1990, 70 (3): 591-614.PubMed
7.
Bang P, Hall K: Insulin-like growth factors as endocrine and paracrine hormones. The insulin-like growth factors Structure and biological junctions. Edited by: PN S. 1992, New York: Oxford University Press, 151-177.
8.
9.
Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S: Osteoporosis and skeletal fractures in chronic liver disease. Gut. 1990, 31 (1): 82-87. 10.1136/gut.31.1.82.PubMedCentralCrossRefPubMed
10.
Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR: Prevalence and prediction of osteopenia in chronic liver disease. Hepatology. 1990, 12 (2): 273-280. 10.1002/hep.1840120214.CrossRefPubMed
11.
Schimpff RM, Lebrec D, Dannadieu M, Repellin AM: Serum somatomedin activity measured as sulphation factor in peripheral, hepatic and renal veins of patients with alcoholic cirrhosis. Acta Endocrinol (Copenh). 1978, 88 (4): 729-736.
12.
Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H: Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metabolism. 1992, 41 (4): 377-381. 10.1016/0026-0495(92)90071-H.CrossRefPubMed
13.
Castilla-Cortazar I, Garcia M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, Diaz M, Prieto J: Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology. 2000, 31 (3): 592-600. 10.1002/hep.510310308.CrossRefPubMed
14.
Mirpuri E, Garcia-Trevijano ER, Castilla-Cortazar I, Berasain C, Quiroga J, Rodriguez-Ortigosa C, Mato JM, Prieto J, Avila MA: Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I. Int J Biochem Cell Biol. 2002, 34 (3): 242-252. 10.1016/S1357-2725(01)00123-6.CrossRefPubMed
15.
Quiroga J, Beloqui O, Castilla A: Liver cirrhosis. Hepatobiliary Disease. Edited by: Prieto J, RJ S. 1992, Berlin, Heidelberg: Springer-Verlag, 323-415.
16.
Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995, 95 (6): 2581-2586. 10.1172/JCI117959.PubMedCentralCrossRefPubMed
17.
Mawer EB, Klass HJ, Warnes TW, Berry JL: Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci (Lond). 1985, 69 (5): 561-570.CrossRef
18.
Castilla-Cortazar I, Quiroga J, Prieto J: Insulin-like growth factor-I, liver function, and hypogonadism in rats with experimentally induced cirrhosis. Hepatology. 2000, 31 (6): 1379-10.1053/jhep.2000.7886.CrossRefPubMed
19.
Castilla-Cortazar I, Prieto J, Urdaneta E, Pascual M, Nunez M, Zudaire E, Garcia M, Quiroga J, Santidrian S: Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology. 1997, 113 (4): 1180-1187. 10.1053/gast.1997.v113.pm9322513.CrossRefPubMed
20.
Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, Santidrian S, Prieto J: Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol. 1998, 28 (1): 122-131. 10.1016/S0168-8278(98)80211-0.CrossRefPubMed
21.
Castilla-Cortázar I, Guerra L, Puche JE, Muñoz U, Barhoum R, Escudero E, Lavandera JL: An experimental model of partial insulin-like growth factor-1 deficiency in mice. J Physiol Biochem. 2013, doi:10.1007/s13105-013-0287-y
22.
Andress DL, Birnbaum RS: Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem. 1992, 267 (31): 22467-22472.PubMed
23.
Komori T: Regulation of bone development and maintenance by Runx2. Front Biosci. 2008, 13: 898-903. 10.2741/2730.CrossRefPubMed
24.
Salih DA, Mohan S, Kasukawa Y, Tripathi G, Lovett FA, Anderson NF, Carter EJ, Wergedal JE, Baylink DJ, Pell JM: Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology. 2005, 146 (2): 931-940.PubMedCentralCrossRefPubMed
25.
Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC: Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci USA. 2012, 109 (8): 3143-3148. 10.1073/pnas.1200797109.PubMedCentralCrossRefPubMed
26.
Zhang M, Faugere MC, Malluche H, Rosen CJ, Chernausek SD, Clemens TL: Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res. 2003, 18 (5): 836-843. 10.1359/jbmr.2003.18.5.836.CrossRefPubMed
27.
Yan T, Riggs BL, Boyle WJ, Khosla S: Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem. 2001, 83 (2): 320-325. 10.1002/jcb.1200.CrossRefPubMed
28.
Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S: Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001, 142 (10): 4349-4356. 10.1210/en.142.10.4349.CrossRefPubMed
29.
Nichols TC, Busby WH, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR: Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinology. 2007, 148 (10): 5002-5010. 10.1210/en.2007-0571.CrossRefPubMed
30.
Cohen S: Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. Arthritis Rheum. 2006, 55 (1): 15-18. 10.1002/art.21706.CrossRefPubMed
31.
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993, 75 (1): 59-72.PubMed
32.
33.
Marie PJ, Kassem M: Extrinsic mechanisms involved in age-related defective bone formation. J Clin Endocrinol Metab. 2011, 96 (3): 600-609. 10.1210/jc.2010-2113.CrossRefPubMed
34.
Samura A, Wada S, Suda S, Iitaka M, Katayama S: Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. Endocrinology. 2000, 141 (10): 3774-3782. 10.1210/en.141.10.3774.PubMed
35.
Elis S, Courtland HW, Wu Y, Fritton JC, Sun H, Rosen CJ, Yakar S: Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J Bone Miner Res. 2010, 25 (9): 2051-2058. 10.1002/jbmr.100.PubMedCentralCrossRefPubMed
36.
Rosenbloom AL: Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009, 26 (1): 40-54. 10.1007/s12325-008-0136-5.CrossRefPubMed
37.
Laron Z: Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev. 2008, 5 (3): 766-771.PubMed
38.
Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C: Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol. 2005, 43 (4): 630-636. 10.1016/j.jhep.2005.03.025.CrossRefPubMed
39.
Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J: Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology. 1997, 113 (5): 1682-1691. 10.1053/gast.1997.v113.pm9352873.CrossRefPubMed
40.
Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993, 75 (1): 73-82.CrossRefPubMed
41.
Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA: Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study: the North America ALS/IGF-I study group. Neurology. 1997, 49 (6): 1621-1630. 10.1212/WNL.49.6.1621.CrossRefPubMed
42.
Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I: Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer’s disease. J Neurosci. 2007, 27 (4): 824-831. 10.1523/JNEUROSCI.4345-06.2007.CrossRefPubMed
43.
Ungvari Z, Csiszar A: The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. J Gerontol A Biol Sci Med Sci. 2012, 67 (6): 599-610.CrossRefPubMed
44.
Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JO: Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005, 90 (11): 5937-5941. 10.1210/jc.2004-2088.CrossRefPubMed
45.
Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB: Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes. 2006, 55 (8): 2365-2370. 10.2337/db05-1646.CrossRefPubMed
46.
Switzer M, Rice J, Rice M, Hardin DS: Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab. 2009, 22 (5): 417-424.PubMed
47.
Meyer NA, Barrow RE, Herndon DN: Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats. J Trauma. 1996, 41 (6): 1008-1012. 10.1097/00005373-199612000-00011.CrossRefPubMed
48.
Jeschke MG, Barrow RE, Herndon DN: Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg. 2000, 231 (2): 246-252. 10.1097/00000658-200002000-00014.PubMedCentralCrossRefPubMed
49.
Puche JE, Castilla-Cortazar I: Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med. 2012, 10: 224-10.1186/1479-5876-10-224.PubMedCentralCrossRefPubMed
50.
Castilla-Cortazar I, Picardi A, Tosar A, Ainzua J, Urdaneta E, Garcia M, Pascual M, Quiroga J, Prieto J: Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats. Am J Physiol. 1999, 276 (1 Pt 1): G37-42.PubMed
51.
Castilla-Cortazar I, Aliaga-Montilla MA, Salvador J, Garcia M, Delgado G, Gonzalez-Baron S, Quiroga J, Prieto J: Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats. Liver. 2001, 21 (6): 405-409. 10.1034/j.1600-0676.2001.210607.x.CrossRefPubMed
52.
Castilla-Cortazar I, Pascual M, Urdaneta E, Pardo J, Puche JE, Vivas B, Diaz-Casares A, Garcia M, Diaz-Sanchez M, Varela-Nieto I: Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by Insulin-like Growth Factor I. BMC Gastroenterol. 2004, 4: 12-10.1186/1471-230X-4-12.PubMedCentralCrossRefPubMed
53.
Muguerza B, Castilla-Cortazar I, Garcia M, Quiroga J, Santidrian S, Prieto J: Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta. 2001, 1536 (2–3): 185-195.CrossRefPubMed
54.
Pascual M, Castilla-Cortazar I, Urdaneta E, Quiroga J, Garcia M, Picardi A, Prieto J: Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I. Am J Physiol Gastrointest Liver Physiol. 2000, 279 (2): G319-324.PubMed
55.
Perez R, Castilla-Cortazar I, Nunez M, Prado A, Mirpuri E, Garcia M, Gonzalez Baron S, Picardi A: IGF-I does not improve fat malabsorption in cirrhotic rats. J Physiol Biochem. 2001, 57 (2): 59-60.CrossRef
56.
Perez R, Garcia-Fernandez M, Diaz-Sanchez M, Puche JE, Delgado G, Conchillo M, Muntane J, Castilla-Cortazar I: Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis. World J Gastroenterol. 2008, 14 (17): 2731-2739. 10.3748/wjg.14.2731.PubMedCentralCrossRefPubMed
57.
Picardi A, de Oliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortazar I, Santidrian S, Prieto J: Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol. 1997, 26 (1): 191-202. 10.1016/S0168-8278(97)80026-8.CrossRefPubMed
58.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998, 95 (7): 3597-3602. 10.1073/pnas.95.7.3597.PubMedCentralCrossRefPubMed
59.
Jonsson KB, Wiberg K, Ljunghall S, Ljunggren O: Insulin-like growth factor I does not stimulate bone resorption in cultured neonatal mouse calvarial bones. Calcif Tissue Int. 1996, 59 (5): 366-370. 10.1007/s002239900141.CrossRefPubMed
60.
Marie PJ, Kassem M: Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011, 165 (1): 1-10. 10.1530/EJE-11-0132.CrossRefPubMed
61.
Khosla S, Westendorf JJ, Oursler MJ: Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008, 118 (2): 421-428. 10.1172/JCI33612.PubMedCentralCrossRefPubMed
62.
Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S: Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest. 2001, 107 (1): 73-81. 10.1172/JCI10459.PubMedCentralCrossRefPubMed
63.
Kamangar BB, Gabillard JC, Bobe J: Insulin-like growth factor-binding protein (IGFBP)-1, -2, -3, -4, -5, and -6 and IGFBP-related protein 1 during rainbow trout postvitellogenesis and oocyte maturation: molecular characterization, expression profiles, and hormonal regulation. Endocrinology. 2006, 147 (5): 2399-2410. 10.1210/en.2005-1570.CrossRefPubMed
64.
O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH: Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008, 3 (8): e2942-10.1371/journal.pone.0002942.PubMedCentralCrossRefPubMed
65.
Keller H, Kneissel M: SOST is a target gene for PTH in bone. Bone. 2005, 37 (2): 148-158. 10.1016/j.bone.2005.03.018.CrossRefPubMed
66.
Eriksen EF, Kassem M, Langdahl B: Growth hormone, insulin-like growth factors and bone remodelling. Eur J Clin Invest. 1996, 26 (7): 525-534. 10.1046/j.1365-2362.1996.00292.x.CrossRefPubMed
67.
Rosen CJ, Donahue LR, Hunter SJ: Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 1994, 206 (2): 83-102. 10.3181/00379727-206-43726.CrossRefPubMed
68.
Slootweg MC, Hoogerbrugge CM, de Poorter TL, Duursma SA, van Buul-Offers SC: The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: autocrine/paracrine growth effect of IGFs?. J Endocrinol. 1990, 125 (2): 271-277. 10.1677/joe.0.1250271.CrossRefPubMed
Metadata
Title
IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
Authors
Lucia Guerra-Menéndez
Maria C Sádaba
Juan E Puche
Jose L Lavandera
Luis F de Castro
Arancha R de Gortázar
Inma Castilla-Cortázar
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-271

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

The involvement of MMP-2 and MMP-9 in heart exercise-related angiogenesis

Research

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

Research

Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling

Research

The altered expression profile of microRNAs in cardiopulmonary bypass canine models and the effects of mir-499 on myocardial ischemic reperfusion injury

Research

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate

Research

Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits